capsid76aav.com

1PROGENBiotechnikGmbHMaastrae30D-69123HeidelbergTel.
:+49(0)62218278-11Fax:+49(0)62218278-24Email:info@progen.
comWeb:www.
progen.
comApril5,2021/Version:65158/DS-050520ibganti-AAVVP1/VP2/VP3mousemonoclonal,B1,supernatantCat.
No.
65158Quantity5mLNo.
ofexperiments≤200(WB,5mlreactionvolume)ProductdescriptionHostmouseAntibodyTypemonoclonalIsotypeIgG1CloneB1ImmunogenAAV2capsidsPurificationhybridomacellculturesupernatantConjugateunconjugatedFormulationcontains0.
09%sodiumazideStorageshorttermat2-8°C;longtermstorageinaliquotsat-20°C;avoidfreeze/thawcyclesIntendeduseResearchuseonlyTestedspeciesreactivityAAV1,AAV2,AAV3,AAV5,AAV6,AAV7,AAV8,AAV9,AAVrh10ApplicationsTestedapplicationsTesteddilutionsAffinityChromatographyassaydependentImmunocytochemistry(ICC)/Immunofluorescence(IF)assaydependentImmunoprecipitation(IP)assaydependent(mainlyfreeVPproteins)WesternBlot(WB)1:25-1:200BackgroundUsefulforimmunolocalizationstudiesofcapsidformationincombinationwithmonoclonalantibodyA20(Cat.
No.
61055/65155)andrabbitpolyclonalantibodytoAAVcapsidproteins(Cat.
No.
61084).
B1reactswithfreeVP1,VP2andVP3ofadeno-associatedvirus(AAV)andataveryreduceddegreewithassembledcapsids.
VP1andVP2arehighlyenrichedinthenucleus,whilenon-assembledVP3isevenlydistributedinthenucleusandthecytoplasm.
Epitopemappingexperiments(Wobus,C.
E.
etal.
,2000)identifiedaa726toaa733(commontoall3VPproteins)asthespecificbindingregion.
Theantibodyisalsousefulforcharacterizationofdifferentstagesofinfection.
WobusCA,Hügle-DrrB,GirodA,PetersenG,HallekM,KleinschmidtJA:Monoclonalantibodiesagainsttheadeno-2PROGENBiotechnikGmbHMaastrae30D-69123HeidelbergTel.
:+49(0)62218278-11Fax:+49(0)62218278-24Email:info@progen.
comWeb:www.
progen.
comApril5,2021/Version:65158/DS-050520ibgassociatedvirustype2(AAV-2)capsid:EpitopemappingandidentificationofcapsiddomainsinvolvedinAAV-2-cellinteractionandneutralizationofAAV-2infection.
JVirol74,9281-9293(2000).
PublicationSpeciesApplicationZhang,R.
etal.
Divergentengagementsbetweenadeno-associatedviruseswiththeircellularreceptorAAVR.
Nat.
Commun.
10,3760(2019)AAVWBBlessing,D.
etal.
ScalableProductionofAAVVectorsinOrbitallyShakenHEK293Cells.
Mol.
Ther.
Methods.
Clin.
Dev.
13,14-26(2019)humanWBWu,Y.
etal.
DevelopmentofVersatileandFlexibleSf9PackagingCellLine-DependentOneBacSystemforLarge-ScaleRecombinantAdeno-AssociatedVirusProduction.
Hum.
Gene.
Ther.
Methods.
30,172-183(2019)AAV2WBFeiner,R.
etal.
rAAVEngineeringforCapsid-ProteinEnzymeInsertionsandMosaicismRevealsResiliencetoMutational,StructuralandThermalPerturbations.
Int.
J.
Mol.
Sci.
20,(2019)AAV2WBLe,D.
etal.
Adeno-associatedviruscapsidproteinexpressioninEscherichiacoliandchemicallydefinedcapsidassembly.
Sci.
Rep.
9,18631(2019)AAV2WBSavy,A.
etal.
GeneticsinstabilityofwtAAV2genomeandAAVpromoteractivitiesintheBaculovirus/Sf9cellssystem.
PLoS.
One.
13,e0199866(2018)AAV2WBSavy,A.
etal.
ImpactofInvertedTerminalRepeatIntegrityonrAAV8ProductionUsingtheBaculovirus/Sf9CellsSystem.
Hum.
Gene.
Ther.
Methods.
28,277-289(2017).
AAV8WBTseng,Y.
-S.
etal.
Generationandcharacterizationofanti-Adeno-associatedvirusserotype8(AAV8)andanti-AAV9monoclonalantibodies.
J.
Virol.
Methods236,105–110(2016).
AAV1AAV2AAV3AAV5AAV6AAV7AAV9dotblotMietzsch,M.
etal.
OneBac:PlatformforScalableandHigh-TiterProductionofAdeno-AssociatedVirusSerotype1–12VectorsforGeneTherapy.
Hum.
GeneTher.
25,212–222(2014).
AAV1AAV2AAV3AAV5AAV6AAV7AAV8AAV9AAVrh10WBNaumer,M.
etal.
PropertiesoftheAdeno-AssociatedVirusAssembly-ActivatingProtein.
J.
Virol.
86,13038–13048(2012).
AAV2WBdotblotSonntag,F.
etal.
TheAssembly-ActivatingProteinPromotesCapsidAssemblyofDifferentAdeno-AssociatedVirusSerotypes.
J.
Virol.
85,12686–12697(2011).
AAV1AAV2AAV5AAV8AAV9WBKuck,D.
,Kern,A.
&Kleinschmidt,J.
A.
DevelopmentofAAVserotype-specificELISAsusingnovelmonoclonalantibodies.
J.
Virol.
Methods140,17–24(2007).
AAV1AAV5AAV6WBICC-IFGrimm,D.
,Kay,M.
A.
&Kleinschmidt,J.
A.
Helpervirus-free,opticallycontrollable,andtwo-plasmid-basedproductionofadeno-associatedvirusvectorsofserotypes1to6.
Mol.
Ther.
7,839–850(2003).
AAV2WBYan,Z.
etal.
UbiquitinationofbothAdeno-AssociatedVirusType2and5CapsidProteinsAffectstheTransductionEfficiencyofRecombinantVectors.
J.
Virol.
76,2043–2053(2002).
AAV2AAV5WBZhang,H.
-G.
etal.
AdditionofSix-His-TaggedPeptidetotheCTerminusofAdeno-AssociatedVirusVP3DoesNotAffectViralTropismorProduction.
J.
Virol.
76,12023–12031(2002).
AAV2WBWobus,C.
E.
etal.
Monoclonalantibodiesagainsttheadeno-associatedvirustype2(AAV-2)capsid:epitopemappingandidentificationofcapsiddomainsinvolvedinAAV-2-cellinteractionandneutralizationofAAV-2infection.
J.
Virol.
74,9281–93(2000)AAV2epitopemappingWistuba,A.
etal.
SubcellularCompartmentalizationofAdeno-AssociatedVirusType2Assembly.
J.
Virol.
71,1341–1352(1997).
AAV2WBIPICC-IF3PROGENBiotechnikGmbHMaastrae30D-69123HeidelbergTel.
:+49(0)62218278-11Fax:+49(0)62218278-24Email:info@progen.
comWeb:www.
progen.
comApril5,2021/Version:65158/DS-050520ibgWistuba,A.
,Weger,S.
,Kern,A.
,Rgen,J.
&Kleinschmidt,A.
IntermediatesofAdeno-AssociatedVirusType2Assembly:IdentificationofSolubleComplexesContainingRepandCapProteins.
J.
Virol.
69,5311–5319(1995).
AAV2WBProductImages